6月2日，Revolution Medicines盘中上涨5.11%，报165.445美元/股，成交额7.53亿美元。
消息面上，ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，入组500名既往接受过治疗的转移性胰腺导管腺癌患者。结果显示，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，数据同步发表于《新英格兰医学杂志》。该数据首次将二线胰腺癌中位OS拉长至1年以上，被视为RAS靶向治疗的里程碑突破。奥本海默同步上调目标价至195美元，维持跑赢大盘评级，市场情绪延续乐观。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.